INTRODUCTION

Metabolic alterations are a hallmark of cancer (Figure 1). Studies conducted over the past two decades have established that critical metabolic changes seen in cancer include enhanced uptake of carbon sources, namely glucose and glutamine, relative to non–dividing normal cells. Cancer cells actively consume these nutrients to meet high anabolic demands related to nucleotide and lipid production. Often these mechanisms coincide with production of antioxidants. Catabolic metabolism is also upregulated in cancer. Relative to normal cells, cancer cells do, indeed, upregulate oxidative mitochondrial metabolism (TCA and oxidative phosphorylation).

Many metabolic activities are conserved among cancers; however, several studies have identified metabolic traits specific to certain cancer types, which are either related to specific genetic alterations or to cells/tissues of origin. Intriguingly, some cancer-type-specific metabolic activities show narrow requirements for a particular nutrient, which represents a unique vulnerability of that cancer to therapeutic targeting based on that nutrient. It is clear that both tumor and non–tumor cells are influenced by the availability of nutrients in their microenvironment (Figure 2). In vivo, the concentrations of many circulating nutrients, which are synthesized de novo or absorbed due to dietary intake, are regulated systemically, although concentrations of some nutrients in the tumor interstitial fluid reportedly differ from those seen in plasma.

In addition, some nutrients required by cancer cells are generated by gut microbiota. Cancer patients often show great interest in dietary changes that may mitigate disease progression or augment therapy effects. However, we still lack rigorous clinical evidence supporting the effectiveness of dietary therapies in treating cancer, and the rationale for recommending dietary change is often not solid. Thus, some patients are, unfortunately, cheated by deceitful business practices due to their high motivation to improve survival. Therefore, it is critical for cancer researchers to rigorously evaluate the current status of nutritional approaches to combat cancer. Here, we discuss recent preclinical analysis of the connection between dietary modification and cancer metabolism and report studies that provide a rationale...
2 CALORIC RESTRICTION, FASTING, AND FASTING-MIMETIC DIETS

Calorie restriction (CR) is the only dietary intervention proven to improve health and extend lifespan in mammals, and its benefits likely include lowering the incidence of malignancy. Studies of CR in cancer have a long history: a century ago Moreschi and Rous found that lowering calorie intake delays tumor growth in mouse transplantation models. Although there are many protocols to accomplish CR, the simplest and most popular is fasting. Combined with conventional chemotherapy, short-term or intermittent fasting significantly improves therapeutic responses in mouse xenograft models of human glioma, neuroblastoma, melanoma, and breast cancer. However, because long-term fasting or CR promote body weight loss, and cancer patients are often frail, short-term or intermittent fasting.21

3 KETOGENIC DIET

The ketogenic diet, an approach originally developed to mitigate epilepsy, has also attracted the attention of cancer patients. This diet is high fat and very low in carbohydrates and similar to FMD in terms of low sugar, which may in part explain mechanistic similarities to CR and fasting (Figure 3). Specifically, host responses to the ketogenic diet include lowering of circulating glucose and insulin levels and enhanced beta-oxidation of fatty acids in the liver that produce ketone bodies. The ketogenic diet has been shown to enhance radiotherapy or chemotherapy responses in mouse xenograft models of human lung cancer, although clinical trials in cancer patients have had mixed results.

Nevertheless, a recent preclinical study in mice showed the potential of combining a ketogenic diet with PI3K inhibition. PI3K mediates many pro-oncogenic signals, mainly through the PI3K-AKT and PI3K-mTOR axis, and PI3K activation is one of the most common events in human cancers. PI3K is, thus, a promising therapeutic target in cancer, but clinical trials of PI3K inhibitors have also shown mixed results, possibly due to emergence of resistance mechanisms. Using mouse allograft models of pancreas cancer and acute myeloid leukemia and xenograft models of bladder cancer, Hopkins et al reported disruption of the feedback mechanism that mediates resistance to PI3K inhibition. PI3K is downstream of insulin and its inhibition promotes hyperglycemia by decreasing glucose uptake by normal tissues. High blood glucose, in turn, stimulates insulin release from the pancreas, re-activating PI3K in tumor cells and conferring resistance to PI3K inhibitors. As one means to perturb this feedback mechanism, these authors fed model mice a ketogenic diet and observed enhanced efficacy of PI3K inhibition relative to similarly treated mice fed a normal diet.
4 | POTENTIAL BENEFITS OF FRUCTOSE RESTRICTION

Both ketogenic and FMD diets lower blood glucose. However, unlike glucose, fructose is not scored as a sugar in blood tests. Tumor cells take up fructose via the GLUT5 transporter and metabolize it in the glycolytic pathway. It is well known that the Western diet and sugar-sweetened beverages contain very high levels of fructose, and increased consumption of fructose parallels the prevalence of obesity worldwide. Fructose has the same energy as glucose, but its glycation activity is at least 10 times higher than that of glucose, suggesting potential harmfulness of this sugar. Epidemiological studies have correlated fructose consumption with tumor incidence, particularly in the colon. Importantly, such studies have served as a warning about the hazards of high-dose fructose consumption. However, a recent study in Apc−/− mouse models showed that more typical daily intake of fructose even at moderate doses boosts colon tumorigenesis. These results imply that fructose intake by cancer patients should be carefully monitored, although to our knowledge there are no reports of positive effects of fructose restriction.

5 | MANNOSE SUPPLEMENTATION

Mannose is an epimer of glucose taken up by the same transporter as glucose. Mannose is a substrate in glycan synthesis and is, thus, important for glycosylation of certain proteins. Mammalian cells can synthesize mannose from glucose, and the source of mannose in vivo has been assumed to be glucose. However, a study in rats using a stable isotopomer showed that nearly 90% of orally administered mannose is rapidly absorbed and used to synthesize glycosylated proteins in many tissues. In sharp contrast to fructose, emerging evidence indicates that mannose supplementation could serve as a therapeutic for acute urinary tract infections in women and autoimmune diabetes in mice. In addition, Gonzalez et al (2018) reported that mannose supplementation delays tumor growth and induces tumor regression when combined with chemotherapy in mice. Mannose is metabolized in tumor cells and accumulates as mannose-6-phosphate (M6P) in glycolysis catalyzed by hexokinase. The presence of M6P then inhibits activities of downstream metabolic pathways, including glycolysis,
the TCA cycle and the pentose-phosphate pathway, overall resulting in downregulation of glucose metabolism (Figure 3). The fact that deleterious effects of mannose appear limited to cancer cells is likely due to higher expression of glucose/mannose transporters on tumor cells relative to normal cells, which, therefore, increase mannose uptake in tumor cells. The same study provided evidence that low expression in tumors of phosphor-mannose isomerase, which converts M6P to the glycolytic intermediate fructose-6-phosphate, predicts a positive response to mannose supplementation therapy. Mannose is readily available at pharmacies, and, thus, mannose supplementation has been presumed feasible and safe. Further study is needed to investigate the full potential (and limitations) of mannose supplementation therapy as a cancer treatment.

6 | AMINO ACID RESTRICTION AND SUPPLEMENTATION

Although many national cancer organizations worldwide, including the National Cancer Institute (NCI), in the USA encourage patients to follow a high protein diet during therapy, several studies report that restriction of dietary protein slows tumor growth in animal models. In fact, in humans, high protein intake is linked to cancer and overall mortality. Thus, limiting protein intake may benefit some cancer patients. The potential beneficial effects of a low protein diet include reduction in blood IGF-1 and PI3K-mTOR signaling, as well as increased response to chemotherapy and radiation therapy in cancer patients. The anti–cancer drugs 5-fluorouracil (5-FU) and methotrexate (MTX) block folate metabolism. DHF, dihydrofollic acid; HCY, homocysteine; SAH, S-adenosyl-homocysteine; THF, tetrahydrofolic acid; 5,10-MeTHF, 5,10-methyleneTHF; 5-MeTHF, 5-methylTHF

FIGURE 4 One-carbon metabolism links the folate cycle with the methionine cycle. In this pathway, the methyl group (one-carbon unit) of serine (Ser) is transferred to metabolites in the folate and then methionine cycles. S-adenosylmethionine (SAM) functions as a universal methyl donor for methylation of proteins and nucleotides (denoted as X). The anti–cancer drugs 5-fluorouracil (5-FU) and methotrexate (MTX) block folate metabolism. DHF, dihydrofollic acid; HCY, homocysteine; SAH, S-adenosyl-homocysteine; THF, tetrahydrofolic acid; 5,10-MeTHF, 5,10-methyleneTHF; 5-MeTHF, 5-methylTHF

7 | METHIONINE RESTRICTION AND HISTIDINE SUPPLEMENTATION

One-carbon metabolism links the folate cycle with the methionine (Met) cycle (Figure 4). The folate cycle is important for synthesis of nucleotide precursors, whereas the Met cycle produces S-adenosyl methionine (SAM), a donor of methyl groups in protein and DNA methylation.

One-carbon metabolism consumes the EAA Met and has been a target of anti–cancer drugs such as 5-fluorouracil (5-FU) and methotrexate (MTX). A study in mice showed that restriction of dietary Met augments the efficacy of 5-FU treatment or radiation therapy against patient-derived xenografts of colorectal cancer and autochthonous soft-tissue sarcomas. Met restriction rapidly alters the plasma levels of metabolites in Met, purine, and pyrimidine metabolism in mice and in human volunteers. In addition to Met, the folate cycle (and, hence, one-carbon metabolism) requires serine Ser, as will be discussed below.

Methotrexate inhibits dihydrofolate reductase in the folate cycle and reduces tetrahydrofolic acid (THF) levels. A CRISPR screen conducted in a leukemia cell line followed by metabolic analysis led to the unexpected finding that histidine (His) catabolism activated by His supplementation decreases the THF pool and increases the sensitivity of leukemia cells to MTX.

8 | BRANCHED-CHAIN AMINO ACIDS

Three branched-chain amino acids (BCAA) (leucine, isoleucine, and valine) are all EAA among proteinogenic amino acids. BCAA activate mTOR signaling and protein synthesis and are catabolized to fuel the TCA cycle in both normal and cancer cells. BCAA supplementation is used clinically to mitigate hepatic encephalopathy and promote wound healing after cancer surgery. Although BACC serve as an essential energy source in several malignancies, some clinical studies report that BCAA supplementation benefits liver cancer patients and is associated with prolonged event-free survival. Whether high levels of circulating BCAA are beneficial or harmful to patients is context-dependent, and further studies are needed to address these questions.
Ser is an NEAA synthesized through the Ser synthesis pathway (SSP), a branch from glycolysis. Ser functions in one-carbon metabolism as a one-carbon donor for folate and is also a precursor of glycine (Gly), a direct substrate for glutathione synthesis. Thus, Ser plays important roles in nucleotide synthesis, methylation, and redox homeostasis. A recent study also highlights the Ser function in sphingolipid diversity to support tumor cell growth. Given these key functions, the demand for Ser by cancer cells is high, rendering some cancer cells dependent on exogenous Ser. Recent studies have extensively investigated effects of dietary Ser restriction on tumor growth and therapy. In mouse models, a Ser-free diet (as well as a Ser-free and Gly-free diet) reduces circulating Ser levels and delays the growth of colon cancer, lymphoma, myeloleukemia, and mammary tumors. Synergy between Ser restriction and biguanide treatment, which reduces blood glucose, has also been reported against autochthonous models of mouse lymphoma and colon cancer. By contrast, Kras-driven pancreatic cancer does not respond to Ser restriction, as activated Kras upregulates the expression of genes encoding SSP enzymes, thereby activating de novo Ser synthesis. In addition, some cancers reportedly show amplification of SSP genes and are, thus, less sensitive to Ser restriction. Collectively, a tumor's SSP activity seems to be a key determinant of susceptibility to Ser restriction. In addition to Kras, the transcription factor NRF2, which is frequently activated in cancer, upregulates a set of SSP genes. Thus, NRF2-activated cancers are also likely unresponsive to Ser restriction therapy.

10 | CYSTEINE/ARGININE/ASPARAGINE DEPLETION

Although not dietary approaches, we briefly note three therapies (either under development or already successful) intended to target NEAA availability.

Cysteine (Cys) can be generated by the transsulfuration pathway, but cancer cells also use exogenous cystine, the oxidized form of Cys. Cystine taken up by the cell surface xCT cystine/glutamine exchanger is rapidly converted to Cys. Many tumor cells have high Cys demands because Cys is a glutathione substrate and, hence, is important for maintaining low levels of oxidative stress. L-cyst(e)inase, which degrades both Cys and cystine, is an artificial enzyme developed following saturation mutagenesis of the human cystathionine gamma-lyase. In mice, administration of recombinant L-cyst(e)inase reduces circulating cystine levels and suppresses growth of human prostate cancer lines. The NEAA arginine (Arg) is synthesized by the urea cycle, and certain cancers, including some liver cancers and melanoma, show loss of expression of the enzyme responsible for de novo Arg synthesis and are, thus, dependent on exogenous Arg. Recently, several arginine (Arg)-degrading agents, have been developed, the most advanced being ADI-PEG20, a PEGylated form of recombinant microbial Arg deiminase, which degrades Arg to citrulline and ammonia. Potential anti-cancer effects of this reagent are currently being evaluated in clinical trials (ClinicalTrials.gov, https://clinicaltrials.gov/).

Finally, there is a class of clinical reagents degrading circulating asparagine, among them L-asparaginase. These drugs have already shown significant success even as a monotherapy in the treatment of acute lymphoblastic leukemia. Other types of cancers are less responsive to this approach.

11 | CONCLUSION

We have reviewed studies that suggest that dietary intervention could have a therapeutic effect in cancer treatment. Due to space limitations, we have not summarized additional papers indicating that diet impacts cancer in two other highly significant ways; namely, by modulating immune activity and by altering the composition of gut microbiota. Relevant to the former, we refer interested readers to several excellent reviews of the relationship of diet to anti-tumor immune responses or immunotherapy. Readers interested in literature relevant to the microbiome are encouraged to consult reviews of this emerging field. Most studies summarized here suggest that dietary interventions could serve as adjuvant therapies for cancer, rather than standalone treatments, and these combination therapies are summarized in Figure 5. We also note that dietary

**FIGURE 5** Precision nutrition approaches enhance cancer therapy. Preclinical studies indicate that specific dietary modifications (left) serve as adjuvant therapies with existing cancer therapies (right). Potential target indications of each therapy are shown in parentheses. AML, acute myeloid leukemia; BLCA, bladder carcinoma; BRCA, breast cancer; CRC, colorectal cancer; HR, hormone receptor; PDAC, pancreatic ductal carcinoma; STS, soft-tissue sarcoma.
modifications most often have positive effects in the context of a specific cancer, and there is likely no universal diet beneficial to all cancers or all cancer treatments.

Many questions remain relevant to the connection between diet and metabolism in vivo. Changes in diet composition alter metabolism systemically, and those changes can be difficult to recapitulate in in vitro cell culture. Along these lines, we should pay more attention to nutrient compositions of culture media, which do not always resemble environmental conditions in vivo.

Given that dietary interventions are commonly applied to treat many metabolic diseases, it is impressive that Otto Warburg argued the concept of ‘cancer as metabolic disease’ almost a century ago. Some dietary interventions now appear so promising that detailed clinical assessment is soon anticipated.

ACKNOWLEDGMENTS
We thank M. Oh-uchi for help with preparation of the manuscript. This work was supported by KAKENHI grants from the Ministry of Education, Culture, Sports, Science, and Technology of Japan to MM (20K17203) and NT (19H01036), and by a P-CREATE grant from the Japan Agency for Medical Research and Development to NT (20cm0106174h0001).

DISCLOSURE
The authors have no conflict of interest to declare.

ORCID
Hiroshi Shima https://orcid.org/0000-0002-0857-8929
Nobuhiro Tanuma https://orcid.org/0000-0001-7914-1380

REFERENCES
1. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell. 2012;21:297-308.
2. DeBerardinis RJ, Chandel NS. We need to talk about the Warburg hypothesis. Cancer Cell. 2020;37:127-129.
3. Hensley CT, Faubert B, Yuan Q, et al. Metabolic heterogeneity in human lung tumors. Cell. 2016;164:681-694.
4. Kerr E, Gaude E, Turrell F, Frezza C, Martins CP. Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities. Nature. 2016;531:110-113.
5. Bonnay F, Veloso A, Steinmann V, et al. Oxidative metabolism drives immortalization of neural stem cells during tumorigenesis. Cell. 2020;182:1490-1507.
6. Viale A, Pettazzoni P, Lyssiotis CA, et al. Oncogene ablation-reverts Warburg even Warburg did not anticipate. Cancer Cell. 2020;37:127-129.
7. Mayers JR, Torrence ME, Danai LV, et al. Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers. Science. 2016;353:1161-1165.
8. Yuneva MO, Fan TWM, Allen TD, et al. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab. 2012;15:157-170.
9. Morita M, Sato T, Nomura M, et al. PKM1 confers metabolic advantages and promotes cell-autonomous tumor cell growth. Cancer Cell. 2018;33:355-367.
10. Sato T, Morita M, Nomura M, Tanuma N. Revisiting glucose metabolism in cancer: lessons from a PKM knock-in model. Mol Cell Oncol. 2018;5:e1472054.
11. Nomura M, Morita M, Tanuma N. A metabolic vulnerability of small-cell lung cancer. Oncotarget. 2018;9:32278-32279.
12. Kudo K, Nomura M, Sakamoto Y, et al. Divergent metabolic responses dictate vulnerability to NAMPT inhibition in ovarian cancer. FEBS Lett. 2020;594:1379-1388.
13. Huang F, Ni M, Chalishazar MD, et al. Inosine monophosphate dehydrogenase dependence in a subset of small cell lung cancers. Cell Metab. 2018;28:369-382.
14. Chalishazar MD, Wait SJ, Huang F, et al. MYC-driven small-cell lung cancer is metabolically distinct and vulnerable to arginine depletion. Clin Cancer Res. 2019;25:5107-5121.
15. Kikuchi N, Soga T, Nomura M, et al. Comparison of the ischemic and non-ischemic lung cancer metabolome reveals hyper activity of the TCA cycle and autophagy. Biochim Biophys Acta. 2020;530:285-291.
16. Sullivan MR, Danai LV, Lewis CA, et al. Quantification of microenvironmental metabolites in murine cancers reveals determinants of tumor nutrient availability. Elife. 2019;8:e44235.
17. Shats I, Williams JG, Liu J, et al. Bacteria boost mammalian host NAD metabolism by engaging the deamidated biosynthesis pathway. Cell Metab. 2020;31:564-579.
18. Longo VD, Panda S. Fasting, circadian rhythms, and time-restricted feeding in healthy lifespan. Cell Metab. 2016;23:1048-1059.
19. Moreschi C. Beziehung zwischen ernährung und tumorwachstum. Zimmunfaitsforsch. 1909;2:651-675.
20. Roux P. The influence of diet on transplanted and spontaneous tumors. J Exp Med. 1914;20:433-451.
21. Lee C, Raffaghello L, Brandhorst S, et al. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med. 2012;4:124ra27.
22. Brandhorst S, Choi IY, Wei M, et al. A periodic diet that mimics fasting promotes multi-system regeneration, enhanced cognitive performance, and healthspan. Cell Metab. 2015;22:86-99.
23. Caffa I, Spagnolo V, Vernieri C, et al. Fasting-mimicking diet and hormone therapy induce breast cancer regression. Nature. 2020;583:620-624.
24. de Groot S, Lugtenberg RT, Cohen D, et al. Fasting mimicking diet as an adjuvant to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial. Nat Commun. 2020;11:3083.
25. Lee C, Safdieh FM, Raffaghello L, et al. Reduced levels of IGF-1 mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index. Cancer Res. 2010;70:1564-1572.
26. Wehling JW. History and origin of the ketogenic diet. In: Stafstrom CE, Rho JM, eds. Epilepsy and the Ketogenic Diet. Totowa, NJ: Humana Press; 2004:31-50.
27. Allen BG, Bhätia SK, Buatti JM, et al. Ketogenic diets enhance oxidative stress and radio-chemo-therapy responses in lung cancer xenografts. Clin Cancer Res. 2013;19:3905-3913.
28. Erickson N, Boscheri A, Linke B, Huebner J. Systematic review: iso-caloric ketogenic dietary regimes for cancer patients. Clin Cancer Res. 2010;34:72.
29. Klement RJ. Beneficial effects of ketogenic diets for cancer patients: a realist review with focus on evidence and confirmation. Med Oncol. 2017;34:132.
30. Hopkins BD, Pauli C, Du X, et al. Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature. 2018;560:499-503.
31. Siegel RL, Miller KD, Jemal A. Colorectal cancer mortality rates in adults aged 20 to 54 years in the United States, 1970–2014. JAMA. 2017;318:572-574.
32. Goncalves MD, Lu C, Tutnauer J, et al. High-fructose corn syrup enhances intestinal tumor growth in mice. Science. 2019;363:1345-1349.
33. Alton G, Hasilik M, Niehues R, et al. Direct utilization of mannos for mammalian glycoprotein biosynthesis. Glycobiology. 1998;8:285-295.

34. Domenici L, Monti M, Bracchi C, et al. D-mannose: a promising support for acute urinary tract infections in women. A pilot study. Eur Rev Med Pharmacol Sci. 2016;20:2920-2925.

35. Zhang D, Chia C, Jiao X, et al. D-mannose induces regulatory T cells and suppresses immunopathology. Nat Med. 2017;23:1036-1045.

36. Gonzalez PS, O’Prey J, Cardaci S, et al. Mannose impairs tumour growth and enhances chemotherapy. Nature. 2018;563:719-723.

37. Yin J, Ren W, Huang X, Li T, Yin Y. Protein restriction and cancer. Biochim Biophys Acta Rev Cancer. 2018;1869:256-262.

38. Levine ME, Suarez JA, Brandhorst S, et al. Low protein intake is associated with a major reduction in IGF-1, cancer, and overall mortality in the 65 and younger but not older population. Cell Metab. 2014;19:407-417.

39. Carey BW, Finley LWS, Cross JR, David Allis C, Thompson CB. mTOR signaling in growth, metabolism, and cancer: a nexus of diet and precision medicine. Nat Rev Cancer. 2018;19:634-645.

40. Sanderson SM, Gao X, Dai Z, Locasale JW. Methionine metabolism in health and cancer: a nexus of diet and precision medicine. Nat Rev Cancer. 2019;19:625-637.

41. Gao X, Sanderson SM, Dai Z, et al. Dietary methionine influences therapy in mouse cancer models and alters human metabolism. Nature. 2019;572:397-401.

42. Kanarek N, Keys HR, Cantor JR, et al. Histidine catabolism is a major determinant of methotrexate sensitivity. Nature. 2018;559:632-636.

43. Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168:960-976.

44. Li J, Yin M, Wang D, et al. BCAT2-mediated BCAA catabolism is critical for development of pancreatic ductal adenocarcinoma. Nat Cell Biol. 2020;22:167-174.

45. Hattori A, Tsunoda M, Konuma T, et al. Impact of branched-chain amino acid supplementation on survival in patients with advanced hepatocellular carcinoma treated with sorafenib: a multicenter retrospective cohort study. Hepatol Res. 2016;46:1002-1010.

46. Nojiri S, Fujiwara K, Shinkai N, Iio E, Joh T. Effects of branched-chain amino acid supplementation after radiofrequency ablation for hepatocellular carcinoma: a randomized trial. Nutrition. 2017;33:20-27.

47. Mattaini KR, Sullivan MR, Vander Heiden MG. The importance of serine metabolism in cancer. J Cell Biol. 2016;214:249-257.

48. Yang M, Vousden KH. Serine and one-carbon metabolism in cancer. Nat Rev Cancer. 2016;16:650-662.

49. Muthusamy T, Cordes T, Handzlik MK, et al. Serine restriction alters sphingolipid diversity to constrain tumour growth. Nature. 2020;586:790-795.

50. Maddocks ODK, Athineos D, Cheung EC, et al. Modulating the therapeutic response of tumours to dietary serine and glycine starvation. Nature. 2017;544:372-376.

51. Sullivan MR, Mattaini KR, Dennstedt EA, et al. Increased serine synthesis provides an advantage for tumors arising in tissues where serine levels are limiting. Cell Metab. 2019;29:1410-1421.

52. Locasale JW, Grassian AR, Melman T, et al. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet. 2011;43:869-874.

53. DeNicola GM, Chen P, Mullarky E, et al. NRF2 regulates serine biosynthesis in non-small cell lung cancer. Nat Genet. 2015;47:1475-1481.

54. Ishimoto T, Nagano O, Yae T, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell. 2011;19:387-400.

55. Cramer S, Saha A, Liu J, et al. Systemic depletion of L-cyst(e)line with cyst(e)line increases reactive oxygen species and suppresses tumor growth. Nat Med. 2017;23:120-127.

56. Kanarek N, Keys HR, Cantor JR, et al. Histidine catabolism is a major determinant of methotrexate sensitivity. Nature. 2018;559:632-636.

57. Phillips MM, Sheaff MT, Szlosarek PW. Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges. Cancer Res Treat. 2013;45:251-262.

58. Haskell CM, Canellos GP, Leventhal BG, et al. L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med. 1969;281:1028-1034.

59. Gwinn DM, Lee AG, Briones-Martin-Del-Campo M, et al. Oncogenic α-ketoglutarate maintains the pluripotency of embryonic stem cells. Nature. 2015;518:413-416.

60. DeNicola GM, Chen P, Mullarky E, et al. NRF2 regulates serine metabolism in cancer. Cell Metab. 2018;559:500-504.

61. Andrejeva G, Rathmell JC. Similarities and distinctions of cancer and immune metabolism in inflammation and tumors. Cell Metab. 2017;26:49-70.

62. Leone RD, Powell JD. Metabolism of immune cells in cancer. Nat Rev Cancer. 2020;20:516-531.

63. Jung J, Zeng H, Horng T. Metabolism as a guiding force for immunity. Nat Cell Biol. 2019;21:85-93.

64. Garrett WS. Cancer and the microbiota. Science. 2015;348:80-86.

65. Poutahidis T, Kleinewietfeld M, Erdman SE. Gut microbiota and immunotherapy? Nat Rev Immunol. 2020;20:522-528.

66. Finlay BB, Goldszmid R, Honda K, Trinchieri G, Wargo J, Zitvogel L. The microbiome in cancer immunotherapy. Nat Rev Immunol. 2015;15:348:80-86.

67. Buttgereit F, Brand MD. A hierarchy of ATP-consuming processes in mammalian cells. Biochem J. 1995;312:163-167.

How to cite this article: Morita M, Kudo K, Shima H, Tanuma N. Dietary intervention as a therapeutic for cancer. Cancer Sci. 2021;112:498–504. https://doi.org/10.1111/cas.14777